Get started
Author

Stacy Pak

Observed name: Stacy Pak PharmD,
OpenAlex ID: A5072299899
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma
2024 · James K. Godfrey, Lei Gao, et al. · Blood · 53
Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma
2023 · Shin Yeu Ong, Stacy Pak, et al. · American Journal of Hematology · 35
Outpatient CAR T-Cell Therapy as Standard of Care: Current Perspectives and Considerations
2024 · Katie Gatwood, Zahra Mahmoudjafari, et al. · Clinical Hematology International · 24
PDF
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
2022 · Swetha Kambhampati Thiruvengadam, Monica Saumoy, et al. · Blood · 22
PDF
Real-world infectious complications of CD3/CD20 bispecific antibodies in relapsed/refractory non-Hodgkin lymphoma
2025 · Annie Xiao, Lu Chen, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 7
Real‐world experience of axicabtagene ciloleucel, a CD19‐directed CAR T‐cell therapy, in the second‐line treatment of early relapsed or primary refractory large B‐cell lymphoma
2024 · Tamer Othman, John H. Baird, et al. · British Journal of Haematology · 5
High Incidence of Cytomegalovirus Infection in Patients Receiving Standard of Care CD19- or BCMA-Targeted CAR-T Cell Therapies for Hematologic Malignancies
2026 · Tamer Othman, John H. Baird, et al. · Transplantation and Cellular Therapy · 1
High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.
2025 · Swetha Thiruvengadam, Nishita Matangi, et al. · Blood · 1
Real-world outcomes of frontline polatuzumab-rchp and impact of frailty in older adults with diffuse large B-cell lymphoma
2025 · Varun Iyengar, Jomel Meeko Manzano, et al. · Blood · 1
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetration
2025 · Lei Gao, Avyakta Kallam, et al. · Blood Advances · 1
PDF
Outpatient Brexucabtagene Autoleucel in B‐Cell Acute Lymphoblastic Leukemia and Mantle Cell Lymphoma
2025 · Tamer Othman, John H. Baird, et al. · American Journal of Hematology · 1
PDF
High Incidence of Cytomegalovirus (CMV) Reactivation in Patients Receiving CAR T-Cell Therapy.
2024 · Tamer Othman, John Baird, et al. · Transplantation and Cellular Therapy · 1
Cyclin-Dependent Kinase 5 Contributes to Bruton’s Tyrosine Kinase Inhibitor Resistance via the IRE1α/XBP1 Axis in Mantle Cell Lymphoma
2026 · Alexey Danilov, Sonia Rodriguez-Rodriguez, et al. · Research Square
PDF
The Clinical Impact And Cost-Effectiveness Of Incorporating Circulating Tumour DNA In Diffuse Large B-Cell Lymphoma
2026 · Swetha Kambhampati, Monica Saumoy, et al. · SSRN Electronic Journal
PDF
Multi-center real world analysis of treatment outcomes of non-COVALENT btki, pirtobrutinib, in patients with COVALENT btki relapsed/refracdtory Mantle Cell Lymphoma
2025 · Paolo Lopedote, Adrienne Nedved, et al. · Blood
Real World Accelerated Step-Up Dosing of Teclistamab and Talquetamab in the Outpatient Setting is Feasible and Associated with Low Incidence of Cytokine Release Syndrome
2025 · Phuong Dao, Thao Nguyen, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-817 Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter Study
2025 · Jessica Chicola, Jomel Meeko Manzano, et al. · Clinical Lymphoma Myeloma & Leukemia
ABCL-817: Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter Study
2025 · Jessica Chicola, Jomel Meeko Manzano, et al. · Clinical Lymphoma Myeloma & Leukemia
Bispecific Antibody Treatment for Diffuse Large B Cell Lymphoma, a Real-World Evidence (RWE) Study
2025 · Geoffrey Shouse, Swetha Thiruvengadam, et al. · Transplantation and Cellular Therapy
Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible
2024 · Tamer Othman, John H. Baird, et al. · Blood
Revolutionizing Hematologic Cancer Treatment: The Promise of Bispecific T-Cell Engagers
2023 · Lihua E. Budde, Stacy Pak, et al. · Journal of the National Comprehensive Cancer Network
PDF
Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.
2022 · Swetha Kambhampati, Monica Saumoy, et al. · Journal of Clinical Oncology
Works count: 22
Citation count: 152
H-index: 5
I10-index: 4
Year
Topic
Type